Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
Tens of thousands of Brazilian and Mexican men are diagnosed with prostate cancer every year. In recent years, there have been multiple clinical advances in the field, with new therapies offering longer survival times, milder safety and tolerability profiles and improved quality of life over existing treatments. However, those achievements have come with a hefty price tag and while the new therapies have become the standard of care in the United States and Europe, Brazil’s and Mexico’s cost-constrained markets are still struggling to widely adopt them in their medical practice. The future will bring more new prostate cancer therapies, and while prescribers are eager to use emerging agents, limited budgets will restrict their uptake and, in an increasingly competitive market, only drugs that meet both clinical and economic expectations will succeed. This A&R analysis provides key insights for navigating the prostate cancer market in Brazil and Mexico, uncovering payer and prescriber expectations in each country.
Already a Client? Log in to access this report.
Natalia Reoutova, , is a senior business insights analyst in the oncology division at Decision Resources Group. Ms. Reoutova has worked on a range of oncology indications including prostate cancer and malignant melanoma. She has authored reports on non-small-cell lung cancer and colorectal cancer, and worked on publications covering both the major and emerging pharmaceutical markets. Natalia Reoutova holds a in natural sciences (specializing in pharmacology) from the University of Cambridge and a in drug discovery from the University of London. Her postgraduate research focused on developing small-molecule inhibitors of oncogenic transcription factors. Prior to working at Decision Resources, she was responsible for planning and estimating the cost of clinical trials at Pharm-Olam International.